Downregulation of Cav-1 can decrease the activity of ATP-binding box family G protein subfamily 2 (ABCG2) in BCRP and improve the chemotherapy sensitivity of drug-resistant breast cancer cells. This evidence concerns the gene CAV1 and breast carcinoma.